Review: bDMARDs are linked to increased risk for infection compared with conventional synthetic DMARDs in RA

References

• 1 Aletaha D, Funovits J, Smolen JS. The importance of reporting disease activity states in rheumatoid arthritis clinical trials. Arthritis Rheum. 2008;58:2622-31. [PMID: 18759299] Google Scholar
• 2 Evengall IL, Svensson B, Boonen A, et al, BARFOT study group. Low-dose prednisolone in early rheumatoid arthritis inhibits collagen type I degradation by matrix metalloproteinases as assessed by serum 1CTP—a possible mechanism for specific inhibition of radiological destruction. Rheumatology (Oxford). 2013;52:733-42. [PMID: 23275387] Google Scholar
• 3 Wolfe F, Michaud K. Resistance of rheumatoid arthritis patients to changing therapy: discordance between disease activity and patients' treatment choices. Arthritis Rheum. 2007;56:2135-42. [PMID: 17599730] Google Scholar
• 4 van Vollenhoven RF, Geborek P, Forslind K, et al; Swefot Study Group. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet. 2012;379:1712-20. [PMID: 22464340] Google Scholar